Yunnan Key Laboratory of Pharmacology for Natural Products is approved by the people's government of Yunnan province in 1992, relying on the construction of Kunming Medical University, which is the first batch of provincial key laboratory engaged in preclinical pharmacodynamic evaluation of new drug, pharmacology research in Yunnan province and safety evaluation of professional institutions. It is an important base for training high-level professionals of new drug research and development in Yunnan Province. The key laboratory is located in the No.4 Scientific Research Building of Kunming Medical University, covering an area of 4,800 square meters. Based on the abundant resources of natural products, folk medicine and medicine of ethnic minorities in Yunnan, the laboratory focuses on core issues of new drug research and the difficulties to be solved by pharmaceutical enterprises in Yunnan, the laboratory builds an independent innovative drug research and development platform and a distinctive pharmaceutical discipline, providing strong scientific and technological support for the improvement of pharmaceutical education and the development of pharmaceutical industry in Yunnan province.
After 30 years of development, the key laboratory has formed a stable research direction on tumor pharmacology, cardiovascular and cerebrovascular pharmacology, endocrine and metabolic pharmacology, respiratory pharmacology, pharmacokinetics, anti-inflammatory immunopharmacology, etc. From molecular, cellular, organ, animal to other levels, we establish in vitro activity screening system, target and mechanism study system and in vivo study of disease animal model system, driving overall development of pharmaceutical sciences.
The research team of tumor pharmacology was established by Professor Qing Chen. The research team has been engaged in the research of tumor pharmacology and tumor biology for a long time, mainly including the screening and discovery of anti-tumor active substances, pre-clinical pharmacodynamic evaluation and mechanism of action research. The high susceptibility genes of tumor were screened and found in clinic and their functions were verified. At present, the research group has a complete set of equipment and research platform for pharmacology and cell or molecular biology research, presided over and completed a number of international and domestic major scientific research projects, and achieved a series of original achievements in the field of tumor pharmacology and tumor biology research.
The cardiovascular pharmacology research team led by Professor Chen Peng has carried out systematic scientific research with modern pharmacological theories and techniques, focusing on the special medicinal plant resources of Yunnan, such as Yunnan notoginseng, Erigeron breviscapus, gastrodiaelata and Phyllumphyllum, focusing on hypertension, atherosclerosis, acute coronary syndrome and other extremely harmful clinical diseases.
The Endocrine and Metabolic Pharmacology research team, led by Prof. Shen Zhiqiang, is dedicated to the study of anti-osteoporosis drugs and their mechanisms of action. In recent years, the research team confirmed that geranium can promote the osteogenic differentiation of bone marrow mesenchymal stem cells and play an anti-osteoporosis role, and made a series of original achievements in this field.
The research team of Professor Yang Weimin mainly focuses on the research and development of new drugs for COPD, diabetic vascular complications and vascular dementia, focusing on the unique medicinal plant resources of Yunnan province, hairy-throated sphingyls, Erigeron brevs and Gastrodiagastrodia. Preclinical research on the main active component of the main diterpenoid compound of hairy-throated sphingyls in Yunnan Province is carried out for the prevention and treatment of Class I new drugs for chronic obstructive pulmonary disease. A Class I new drug product has been preliminarily developed, which lays the foundation for the application for clinical research in the next step. Currently, relevant achievements are being transformed.
The pharmacokinetic research team led by Prof. Wang Wei is committed to the study of the brain drug targeting effect of natural drugs, focusing on the study of molecular entities crossing the blood-brain barrier and their distribution and regulation mechanism in the central nervous system, as well as the interpretation of the dynamic behavior of stereoselective biotransformation under the action of polymorphic CYP450 enzyme in the brain.
In 2020, a 600MHz NMR spectrometer was added to the key laboratory, which is used to study molecular structure, molecular dynamics and pharmacometomics, etc., providing a strong guarantee for expanding the scope and level of laboratory services and providing external technical support.
During the period from the 13th Five-Year Plan to the 14th Five-Year Plan, the key laboratory dedicated in pharmacology, while focusing on extraction and separation, activity screening, target and mechanism research, pharmacodynamic evaluation, and drug formation research and constantly enhancing interdisciplinary integration. In 2018, the School of Pharmaceutical Sciences and Key Laboratory was authorized to confer the doctorate degree. In 2019, the provincial Pharmacy postdoctoral Research mobile Station was officially awarded. In 2021, pharmacology and Toxicology entered the top 1% of ESI ranking.
